CEDARVILLE – Rocco Rotello, Ph.D., associate professor of pharmaceutical sciences at Cedarville University, recently received a joint patent in conjunction with his work in stabilizing blood vessels to treat serious clinical conditions. Rotello’s work continues out of a partnership with the Cincinnati-based startup, Aerpio Therapeutics, a clinical-stage biopharmaceutical company.
“Many others have tried to develop similar antibodies in the past, but have failed to show the functionality of their work,” he said. “Our work is unique and thus patent-worthy because it has shown preliminarily that our antibody works in the ways we had hoped it would here in these late stages of preclinical development.”
Rotello said that the reception of this patent is gratifying because it demonstrates that the work he and Aerpio have done is headed in the right direction. “While we are still in the research phase of developing this therapeutic, we are certainly excited about the potential we see in this antibody,” he said.
Rotello, who previously worked for 16 years at Procter & Gamble Pharmaceuticals, brought his expertise to Cedarville University in summer 2011. Currently he contributes to the school of pharmacy’s research and professional course development. He is among the first to use Cedarville’s newly constructed state-of-the-art Health Sciences Center for academic research.
Located in southwest Ohio, Cedarville University attracts 3,400 undergraduate, graduate and online students to more than 100 areas of study. Inspiring greatness for over 125 years, Cedarville is a Christ-centered learning community recognized nationally for rigorous academic programs, strong graduation and retention rates, accredited professional and health science offerings and leading student satisfaction ratings. Visit the University online at www.cedarville.edu.